Drug intelligence / Profile preview

AST-51X

Development stage: Unknown
Lead developer: Aston Sci

Overview

AST-51X is a biological product in early-stage development, originally developed by Aston SCI. It is being investigated for use in infectious diseases and nervous system diseases, with specific indications including epilepsy and central nervous system infections. As of the latest update, its highest research and development status is at the discovery phase. The precise mechanism of action, molecular targets, modality details, and route of administration have not been disclosed publicly[1].

Beyond the preview

Go deeper on AST-51X.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AST-51X.

Explore the full profile